Clinical trials: Only Child
Infections, Upper Respiratory Tract
The Effect of a Probiotic on Upper Respiratory Tract Infections
This study is a randomized, double-blind, placebo-controlled, two-armed, parallel-group study in healthy children aged 2-6 years.
- Trial name
- PIP-U (NCT03636191)
- Testing
- Probiotic strain
- Where
- United Kingdom
- Volunteers
- 619 people, healthy volunteers welcome
- Sponsor
- Chr Hansen
Encephalitis, Tick-Borne
Study of the Safety, Tolerability and Immune Response of TBE Vaccines Administered to Healthy Children
The purpose of this study is to evaluate the safety, immunogenicity and tolerability of TBE vaccines administered to children.
- Trial name
- NCT00311441
- Testing
- Tick-Borne Encephalitis vaccine
- Where
- Germany
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Novartis
Hepatic Insufficiency
Nintedanib in Volunteers With Hepatic Impairment Compared With Healthy Volunteers
The primary objective of this study is to investigate the effect of mild (Child-Pugh A, score 5-6) and moderate (Child-Pugh B, score 7-9) hepatic impairment on the pharmacokinetics, safety and tolerability of nintedanib, in…
- Trial name
- NCT02191865
- Testing
- Nintedanib
- Where
- Germany
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Hepatic Impairment
Pharmacokinetics Study of FIA586 in Participants With Mild and Moderate Hepatic Impairment
This is a Phase I study designed to characterize the pharmacokinetics (PK), safety, and tolerability of a single oral dose of FIA586 in participants with mild and moderate hepatic impairment (HI) compared to matched healthy…
- Trial name
- NCT04993157
- Testing
- FIA586
- Where
- 2 sites in United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Vaccines, Meningococcal Vaccines
A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to Gardasil and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 11 and 17
This is a clinical study to assess the safety, tolerance and immunogenic response to Gardasil (human papilloma virus (HPV)) and rLP2086 vaccine.
- Trial name
- NCT01461993
- Testing
- rLP2086 and Gardasil, rLP2086, Gardasil
- Where
- 87 sites in United States
- Volunteers
- 2,499 people, healthy volunteers welcome
- Sponsor
- Pfizer
Infectious Disease, Children, Only
Prebiotic Fructans on the Incidence of Acute Infectious Diseases in Children
The study aims to explore whether prophylactic dietary supplementation with prebiotic inulin-type fructans is able to influence the intestinal microbiota and the frequency of infectious disease episodes in kindergarten children…
- Conditions
- Infectious Disease, Children, Only, Diet Modification
- Trial name
- NCT03241355
- Testing
- prebiotic inulin-type fructan
- Volunteers
- 258 people, healthy volunteers welcome
- Sponsor
- Beneo-Institute
Myopia, Progressive, Myopia
Clinical Evaluation of a Myopia Control Lens in Slowing Myopia Progression
This is a monocenter, randomized, controlled, parallel-group, double-masked clinical trial to evaluate the effectiveness of test lens in slowing myopia progression with respect to axial length elongation at baseline compared to a…
- Trial name
- NCT05331378
- Testing
- Test myopia control lenses, Single vision lenses
- Where
- Singapore
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Essilor International
Chronic Kidney Disease
Study of the Influence of Liver Function on Blood Concentrations of Runcaciguat in Participants With Different Degrees of Liver Impairment
Researchers are looking for a better way to treat people with chronic kidney diseases. Before a treatment can be approved for patients to take, researchers do clinical studies to better understand its safety and what happens to…
- Trial name
- NCT04820621
- Testing
- Runcaciguat (BAY1101042)
- Where
- Germany
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Bayer
Typhoid Fever
Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Children, Older Infants and Infants
This phase 2 trial is aimed to obtain information on the safety and immunogenicity of the Vi-CRM197 in children and infants from various age groups in the Philippines where Typhoid Fever is highly endemic and an efficacious…
- Trial name
- NCT01437267
- Testing
- Vi-CRM197 vaccine, Pneumococcal conjugate vaccine, Vi Polysaccharide (PS) vaccine
- Where
- Philippines
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Novartis
Hepatic Insufficiency
A Study to Test How BI 1015550 is Taken up in the Blood of People With and Without Liver Problems
This study is open to adults aged 18 years and older. People without liver problems and people who have mild or moderate liver problems can join the study.
- Trial name
- NCT05661344
- Testing
- BI 1015550
- Where
- Germany
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Soil-Transmitted Helminths
Real World Evaluation of an Albendazole-Ivermectin Coformulation Safety and Effectiveness
An open-label, randomized by school, two-arm pragmatic trial, will be conducted involving two study sites in Sub-Saharan-Africa (SSA), Ghana and Kenya, to evaluate safety and effectiveness of the newly developed fixed dose…
- Trial name
- NCT06282315
- Testing
- Pre-screening Phase, Screenig Phase, Randomization
- Where
- 2 sites in Ghana, Kenya
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Insud Pharma
Pharmacology, Clinical
Study on the Safety of Neladenoson Bialanate, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Dug Given as a Single Oral Dose in Participants With Liver Impairment and Healthy Participants Matched for Age-, Gender-, and Weight
Neladenoson bialanate is currently under clinical development for a condition in which the heart has trouble pumping blood through the body (chronic heart failure).
- Trial name
- NCT04322253
- Testing
- Neladenoson bialanate (BAY 1067197)
- Where
- Germany
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Bayer
Hepatic Impairment
A Single Dose Evaluation of the Effects of Moderate Hepatic Impairment on Deflazacort Pharmacokinetics
This is a non-randomized, open-label, single-dose study to compare the PK of 21-desacetyl-DFZ and, if data permits, deflazacort in 8 subjects with moderate hepatic impairment (based on the Child Pugh classification, Grade B) to…
- Trial name
- NCT02286609
- Testing
- Deflazacort
- Where
- 2 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- PTC Therapeutics
Allergic Rhinitis, Upper Respiratory Infection
Study Evaluating the Pharmacokinetics of Doxylamine Succinate in Children
The primary goal of this study is to characterize the pharmacokinetics of doxylamine succinate in children ages 2 to < 18 years.
- Trial name
- NCT00796315
- Testing
- Doxylamine Succinate USP
- Where
- 6 sites in United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Procter and Gamble
Growth, Learning
Nutritional Supplementation in Children Aged 1-3 Years Experiencing Growth Concerns
This open-label clinical trial will gain evidence of the effect of an oral Nutritional Supplement (NS) to help improve catch-up growth and support learning skills in children with growth concerns.
- Conditions
- Growth, Learning, Toddlers
- Trial name
- NCT04766346
- Testing
- Fortified Cow's Milk-Based Oral Nutritional Supplement
- Where
- Philippines
- Volunteers
- 168 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)
Myopia
Myopia Control With Novel Eye Drops
Myopia currently affects 30% of the world and by 2050, almost 50% of the world will be myopic based on conservative estimates.1 In 2050, this will equate to almost 5 billion people with myopia, and those with high myopia will…
- Trial name
- NCT04301323
- Testing
- BHVI1 eye drops, BHVI2 eye drops, BHVI3 eye drops
- Where
- Vietnam
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Hai Yen Eye Care
Healthy Volunteer
Phase 1 Single-ascending Dose Study to Evaluate Safety and Tolerability of MEDI4920 in Healthy Adults
Phase 1 single IV dose study to evaluate safety and tolerability of MEDI4920
- Trial name
- NCT02151110
- Testing
- MEDI4920 3 mg, MEDI4920 10 mg, MEDI4920 30 mg
- Where
- United Kingdom
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Healthy
Cross-over Study to Evaluate the Palatability of New Orally Disintegrating Tablets (ODTs) of Praziquantel (PZQ) and L-PZQ Versus Current PZQ Tablets in African Children Age 6-11 Years
The primary objective of the trial is to compare the "overall palatability" of the new orally disintegrating L-Praziquantel (L-PZQ ODT), the new racemate PZQ ODT (Rac-PZQ ODT) and the current available racemate PZQ tablets…
- Trial name
- NCT02315352
- Testing
- L-PZQ ODT, Rac-PZQ ODT, Cesol®
- Where
- Tanzania
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Merck KGaA, Darmstadt, Germany
Salmonella Infections
A Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMMA Vaccine Against Invasive Nontyphoidal Salmonella in Adults, Children, and Infants
The purpose of this study is to evaluate the safety, reactogenicity, and immune response of the GlaxoSmithKline (GSK) Vaccines Institute for Global Health (GVGH) invasive nontyphoidal Salmonella-generalized modules for membrane…
- Trial name
- NCT06213506
- Testing
- iNTS-GMMA Dose C, iNTS-GMMA Dose B, iNTS-GMMA Dose A
- Where
- Ghana
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Study of a Single Dose or Two Doses of a Trivalent Inactivated Influenza Vaccine Produced at Shenzhen, China
The main purpose of this trial is to describe the product profile in terms of immunogenicity and safety following administration of trivalent influenza vaccine (split-virion, inactivated) produced at Shenzhen (SP Shz TIV).
- Trial name
- NCT02228980
- Testing
- Shenzhen trivalent influenza vaccine (split virion, inactivated) North Hemisphere (NH) formulation
- Where
- China
- Volunteers
- 602 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company